LILRB2 and cancer: 8 It has been widely acknowledged that HLA‐G is a potent immune inhibitory molecule that can interact with immune inhibitory receptors (particularly ILT2 and ILT4) expressed on various immune effectors.9 As a consequence, HLA‐G expression is favorable when it maintains the foetal–maternal immune tolerance and transplanted graft acceptance; however, it is harmful when it promotes immune evasion by cancer cells or virus‐infected cells.7